Multi-Symptom Cramp Relief Drug Recalled for Manufacturing Deviations
Ultra Seal Corporation recalled 1,351,660 packets of Multi-Symptom Cramp Relief nationwide due to current good manufacturing practice (cGMP) deviations. The recall was voluntarily initiated and affects two lots with expiration dates in January and July 2022.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving manufacturing deviations with no reported illnesses or injuries stated in the source text. The hazard is compliance-based rather than involving known contamination or imminent safety risk, making it a Moderate severity case per the rubric for FDA Class II recalls without reported harm.
Plain-English summary
Ultra Seal Corporation initiated a voluntary nationwide recall of Multi-Symptom Cramp Relief (acetaminophen 325mg and Pamabrom 25mg) in 2-tablet packets. The recall affects 1,351,660 packets manufactured for First Aid Direct in Mason, Ohio.
The recall was initiated due to current good manufacturing practice (cGMP) deviations. The affected lots are AK9453 (Expiration Date 01/2022) and AK9716 (Expiration Date 07/2022).
The product was distributed nationwide within the United States. Consumers should stop using affected packets and contact the manufacturer or healthcare provider with questions. This Class II recall was voluntarily initiated by the firm on January 24, 2022, and was terminated on October 16, 2023.
The recalled product
- Product
- Multi-Symptom Cramp Relief (acetaminophen 325mg and Pamabrom 25mg), 2- tablet packets, Mfd. for First Aid Direct, Mason, OH 45040
- Manufacturer
- Ultra Seal Corporation
- Hazard
- cGMP-deviation
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: AK9453
- Exp. Date 01/2022
- AK9716
- 07/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27